Consistently, tumor biopsies of BCC showed a 10q deletion containing SUFU, which was associated with the partial loss of SUFU function but was not sufficient to drive resistance to vismodegib in the absence of other co-occurring alterations, such as focal GLI2 amplifications [80]. The gene discussed is GLI2; the disease is skin basal cell carcinoma.